VNTA Ventana Biotech Inc (PK)

Ventana Biotech Inc. ("Ventana") (PINK SHEETS: VNTA), a biotechnology company developing an appetite-suppressing and stress reducing chewing gum, today announced that it has retained legal counsel for the purpose of filing a Form S-1 Registration Statement with the US Securities and Exchange Commission.

The shares to be included in the Registration Statement will be all those restricted shares currently held by non-affiliated shareholders as well as new shares to be issued by Ventana. Ventana will not receive any of the proceeds from the sale of the shares by its stockholders but intends to use the net proceeds it receives from the offering of the new shares for general corporate purposes and for the acquisition of further intellectual property and patent rights. The number of shares to be registered and the price range for the offering have not yet been determined.

The Company expects to file the Registration Statement relating to these securities in the 4th quarter of 2009. These securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale of securities would be unlawful prior to their registration and qualification under the securities laws of any such state or jurisdiction.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

For more information about Ventana Biotech Inc please contact investor@ventanabiotech.com.

Contacts: Ventana Biotech Inc Janne Christensen, CEO BCB 1 Bachstrasse Butschwil CH-9606 Switzerland Mobile: +44 7930 732 426